ENTITY
Pharmaron Beijing

Pharmaron Beijing (3759 HK)

153
Analysis
Health CareChina
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
08 Sep 2021 18:48

Novotech Health IPO: Valuation First-Look

Novotech is pre-marketing an HKEx IPO to raise $0.5-1.0 billion. In this note, we present our forecasts and take the first look at Novotech's...

Logo
285 Views
Share
06 Sep 2021 22:26

Novotech Health IPO: A Solid Start to 2021

We examine the PHIP which discloses the 1Q21 results along with additional disclosures and recent developments. Overall, we continue to maintain...

Logo
325 Views
Share
04 Sep 2021 22:37

Novotech Health IPO Initiation: On-Demand Science

Novotech is set to pre-market an HKEx IPO to raise up to $1.5 bn. Novotech’s fundamentals are solid and the IPO is worth a look for investors...

Logo
296 Views
Share
31 Aug 2021 05:15

EM Fund Positioning:  All You Need to Know

In this analysis, we provide a detailed overview of investor positioning among 250 active Global Emerging Market funds with combined AUM of $500bn.

Logo
311 Views
Share
12 Aug 2021 09:23

Pre-IPO Ambio Pharmaceuticals - The Particularity of Peptide Drugs, the Strength and the Concerns

The article mainly analyzed Ambio Pharmaceuticals in terms of the particularity of peptide drugs & industry characteristics, the strength of its...

Logo
526 Views
Share
x